YAP1 and hepatocellular carcinoma: Tamoxifen-mediated GPER activation downregulated RhoA levels, which in turn reduced the phosphorylation of MLC-2 (an actomyosin regulatory protein that controls ECM contractility in HSCs) and also suppressed YAP activation; actinomycin and YAP activation are necessary for the development of fibrosis in HCC tumors [157].